Siramesine

Drug Profile

Siramesine

Alternative Names: LU-28179

Latest Information Update: 04 Sep 2014

Price : $50

At a glance

  • Originator Lundbeck A/S
  • Developer Lundbeck A/S; Onxeo SA
  • Class Antidepressants; Anxiolytics; Indoles; Spiro compounds
  • Mechanism of Action Sigma-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anxiety disorders; Cancer; Major depressive disorder

Most Recent Events

  • 04 Sep 2014 Discontinued - Preclinical for Cancer in Denmark (PO)
  • 01 Aug 2014 TopoTarget has merged with BioAlliance Pharma to form Onxeo SA
  • 17 Sep 2008 Siramesine is still in preclinical trials for Cancer in Denmark
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top